<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02266485</url>
  </required_header>
  <id_info>
    <org_study_id>525.3</org_study_id>
    <nct_id>NCT02266485</nct_id>
  </id_info>
  <brief_title>Pharmacodynamics, Preliminary Pharmacokinetics and Tolerability of BIBB 515 BS or Pravastatin in Hyperlipemic Healthy Male Subjects</brief_title>
  <official_title>Pharmacodynamics, Preliminary Pharmacokinetics and Tolerability After Multiple Oral Doses of 2.5 mg o.d. BIBB 515 BS (Capsule) or Pravastatin 20 mg Over 2 Weeks in Hyperlipemic Healthy Male Subjects (Parallel Group Comparison, Randomized, Placebo Controlled, Partly Double Blind [Pravastatin Open])</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Investigation of pharmacodynamics (inhibition of oxidosqualene cyclase, MES as marker),
      effect on routine lipid profile parameters, safety and preliminary pharmacokinetics
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 1998</start_date>
  <primary_completion_date type="Actual">September 1998</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage changes in total-cholesterol</measure>
    <time_frame>Pre-dose, up to day 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage changes in low density lipoprotein (LDL) - cholesterol</measure>
    <time_frame>Pre-dose, up to day 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage changes in high density lipoprotein (HDL) - cholesterol</measure>
    <time_frame>Pre-dose, up to day 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage changes in apo-lipoprotein B</measure>
    <time_frame>Pre-dose, up to day 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage changes in lipoprotein (a)</measure>
    <time_frame>Pre-dose, up to day 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage changes in triglycerides</measure>
    <time_frame>Pre-dose, up to day 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum concentration of the analyte in plasma at different time points (Cmax)</measure>
    <time_frame>Up 336 hours after first drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reach maximum concentration of the analyte in plasma at different time points (tmax)</measure>
    <time_frame>Up 336 hours after first drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent terminal elimination half-life of the analyte in plasma (t1/2)</measure>
    <time_frame>Up 336 hours after first drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve of the analyte in plasma at different time points (AUC)</measure>
    <time_frame>Up 336 hours after first drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total mean residence time of the analyte in the body (MRTtot)</measure>
    <time_frame>Up 336 hours after first drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent clearance of the analyte in plasma after extravascular multiple dose administration (CL/f)</measure>
    <time_frame>Up 336 hours after first drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent volume of distribution of the analyte during the terminal phase (Vz/f)</measure>
    <time_frame>Up 336 hours after first drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal rate constant of the analyte in plasma (λz)</measure>
    <time_frame>Up 336 hours after first drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically relevant changes from baseline in physical examination</measure>
    <time_frame>Pre-dose and day 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically relevant changes from baseline in 12-lead ECG</measure>
    <time_frame>Pre-dose and day 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically relevant changes from baseline in lens examination</measure>
    <time_frame>Pre-dose and day 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically relevant changes in vital signs (blood pressure, pulse rate, body weight)</measure>
    <time_frame>Pre-dose, up to 324 hours after first drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically relevant changes in laboratory parameters</measure>
    <time_frame>Pre-dose, up to 324 hours after first drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Up to 1 day after last drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Global clinical assessment by the investigator</measure>
    <time_frame>On day 15 after first drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Monoepoxy-squalene (MES) plasma concentration at different time points</measure>
    <time_frame>Pre-dose, up to day 15</time_frame>
    <description>as surrogate marker for squalene inhibition</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BIBB 515 BS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Pravastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIBB 515 BS</intervention_name>
    <arm_group_label>BIBB 515 BS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pravastatin</intervention_name>
    <arm_group_label>Pravastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male caucasian subjects as determined by results of screening

          -  Written informed consent in accordance with good clinical practice (GCP) and local
             legislation given

          -  Age ≥ 18 and ≤ 65 years

          -  Broca ≥ - 20 % and ≤ + 30 %

          -  Cholesterol level ≥ 5.4 mmol/l

        Exclusion Criteria:

          -  Any finding of the medical examination (including blood pressure, pulse rate and ECG)
             deviating from normal and of clinical relevance

          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders

          -  Surgery of gastrointestinal tract (except appendectomy)

          -  Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or
             neurologic disorders

          -  History of orthostatic hypotension, fainting spells or blackouts

          -  Chronic or relevant acute infections

          -  History of allergy/hypersensitivity (including drug allergy) which was deemed relevant
             to the trial as judged by the investigator

          -  Intake of drugs with a long half-life (&gt; 24 hours) (≤ 1 month prior to administration
             or during the trial)

          -  Use of any drugs which might influence the results of the trial (≤ 10 days prior to
             administration or during the trial)

          -  Participation in another trial with an investigational drug (≤ 2 months prior to
             administration or during the trial)

          -  Smoker (&gt; 10 cigarettes or 3 cigars or 3 pipes/day)

          -  Inability to refrain from smoking on study days

          -  Alcohol abuse (&gt; 60 g/day)

          -  Drug abuse

          -  Blood donation &gt; 100 ml (≤ 4 weeks prior to administration or during the trial)

          -  Excessive physical activities (≤ 10 days prior to administration or during the trial)

          -  Any laboratory value outside the reference range of clinical relevance

          -  Abnormal findings at eye lens examination
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2014</study_first_submitted>
  <study_first_submitted_qc>October 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2014</study_first_posted>
  <last_update_submitted>October 16, 2014</last_update_submitted>
  <last_update_submitted_qc>October 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pravastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

